Díaz RRD

Language: Spanish
References: 7
Page: 49-50
PDF size: 169.46 Kb.

Text Extraction

No abstract.

REFERENCES

1. Documento de consenso de GeSIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodefciencia humana, 2020.

2. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. Nov 30 2006; 355 (22): 2283-2296. Available at http://www.ncbi.nlm.nih.gov/entrez/query.

3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed [insert date] [insert page number, table number, etc. if applicable] It is emphasized that concepts relevant to HIV management evolve rapidly. Feb 2021.

4. Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS 2018 Jan 2; 32 (1): 17-23doi: 10.1097/QAD.0000000000001671.

5. Mosqueda y cols.

6. Tashima K, Crofoot G, Tomaka FL, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014;11: 39. Available at: https://www.ncbi.nlm. nih.gov/ pubmed/25926858.

7. Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir / cobicistat / emtricitabine / tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014; 65: e118-20.